Evidence map›Paper›PMID 34649354›Full record

ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2021

A digital health platform for assisting the diagnosis and monitoring of COVID-19 progression: An adjuvant approach for augmenting the antiviral response and mitigating the immune-mediated target organ damage.

Yuval Ishay, Assaf Potruch, Asaf Schwartz, Marc Berg, Khurram Jamil, Samuel Agus, Yaron Ilan

Open access · goldAbstract read
In one paragraph

Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Yuval IshayDepartment of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel. Electronic address: hawkempire@gmail.com.
Assaf PotruchDepartment of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel. Electronic address: poassaf@gmail.com.
Asaf SchwartzDepartment of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel. Electronic address: sch.asaf@gmail.com.
Marc BergAltus Care powered by Oberon Sciences, Denmark, Israel; Department of Pediatrics, Lucile Packard Children's Hospital, Stanford, USA. Electronic address: marc@area9.dk.
Khurram JamilAltus Care powered by Oberon Sciences, Denmark, Israel. Electronic address: khurram@area9.dk.
Samuel AgusAltus Care powered by Oberon Sciences, Denmark, Israel. Electronic address: samugus2@gmail.com.
Yaron IlanDepartment of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel. Electronic address: ilan@hadassah.org.il.
Hadassah Medical Center · ILLucile Packard Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19), which is a respiratory illness associated with high mortality, has been classified as a pandemic. The major obstacles for the clinicians to contain the disease are limited information availability, difficulty in disease diagnosis, predicting disease prognosis, and lack of disease monitoring tools. Additionally, the lack of valid therapies has further contributed to the difficulties in containing the pandemic. Recent studies have reported that the dysregulation of the immune system leads to an ineffective antiviral response and promotes pathological immune response, which manifests as ARDS, myocarditis, and hepatitis. In this study, a novel platform has been described for disseminating information to physicians for the diagnosis and monitoring of patients with COVID-19. An adjuvant approach using compounds that can potentiate antiviral immune response and mitigate COVID-19-induced immune-mediated target organ damage has been presented. A prolonged beneficial effect is achieved by implementing algorithm-based individualized variability measures in the treatment regimen.

Indexed as

COVID-19 Drug TreatmentAlgorithmsAntiviral AgentsChemotherapy, AdjuvantCOVID-19Disease ManagementDisease ProgressionGastrointestinal TractHumansImmunity, CellularImmunity, HumoralMedical InformaticsSeverity of Illness IndexAntiviral AgentsAntiviral responseAntiviral therapyARDSCoronavirusCOVID-19Digital health

Identifiers

PMID34649354
PMCPMC8455249
OpenAlexW3199554003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.